Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to $21.7 million.

  • Ani Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3.13% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 3.13%. This contributed to the annual value of $21.0 million for FY2024, which is 2.89% up from last year.
  • Ani Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $21.7 million in Q3 2025, which was up 0.17% from $21.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $21.8 million during Q1 2025, with a 5-year trough of $12.4 million in Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $20.5 million, with its median value being $21.0 million (2024).
  • Data for Ani Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY surged of 39.68% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $12.8 million in 2021, then surged by 36.96% to $17.5 million in 2022, then increased by 17.02% to $20.4 million in 2023, then increased by 2.89% to $21.0 million in 2024, then climbed by 3.13% to $21.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $21.7 million for Q3 2025, versus $21.7 million for Q2 2025 and $21.8 million for Q1 2025.